Merck Exceeds Quarterly Estimates with Keytruda and New Products, Adjusts 2026 Guidance
Merck reported first-quarter results that exceeded expectations, driven by strong demand for Keytruda and new products. The company narrowed its 2026 revenue guidance and raised its adjusted profit outlook, despite a loss attributed to the acquisition of Cidara Therapeutics.
Tickers: $MRK
Topics: Acquisition Charges Earnings Keytruda Merck Pharmaceuticals Profit Outlook